1. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
- Author
-
Takahiro Ishiguro, Yuji Sano, Shun-ichiro Komatsu, Mika Kamata-Sakurai, Akihisa Kaneko, Yasuko Kinoshita, Hirotake Shiraiwa, Yumiko Azuma, Toshiaki Tsunenari, Yoko Kayukawa, Yukiko Sonobe, Natsuki Ono, Kiyoaki Sakata, Toshihiko Fujii, Yoko Miyazaki, Mizuho Noguchi, Mika Endo, Asako Harada, Werner Frings, and Etsuko Fujii
- Subjects
TUMORS ,TUMOR genetics ,T cells ,IMMUNOTHERAPY ,BISPECIFIC antibodies ,THERAPEUTIC use of immunoglobulins ,GENE therapy - Abstract
The article focuses on the immunotherapeutic properties of bispecific T cell-redirecting antibody (TRAB) for the treatment of tumors. Topics discussed include the capacity of CD3 gene on redirecting T cells and antigen on tumor cells, the clinical response of bispecific T cell engager blinatumomab against hematological malignancies, and developed humanized immunoglobulin G-structured TRAB ERY974 which has the capacity to kill various types of tumors.
- Published
- 2017
- Full Text
- View/download PDF